Aptose Biosciences (TSE:APS) Share Price Passes Above 50 Day Moving Average – Here’s Why

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$2.19 and traded as high as C$2.26. Aptose Biosciences shares last traded at C$2.26, with a volume of 781 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners lowered shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Aptose Biosciences Price Performance

The stock has a 50-day moving average price of C$2.19 and a two-hundred day moving average price of C$1.94. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The stock has a market cap of C$5.77 million, a price-to-earnings ratio of 3.28 and a beta of -0.46.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share (EPS) for the quarter. As a group, equities research analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.